ข้อมูลจากบทคัดย่อ
ยังไม่มีสรุปภาษาไทยสำหรับระเบียนนี้
ด้านล่างเป็นบทคัดย่อต้นฉบับภาษาอังกฤษจากข้อมูลบรรณานุกรม โปรดตรวจบทความต้นฉบับก่อนอ้างอิง
Background/Objectives: Waning immunity after primary COVID-19 vaccination supports evaluation of additional doses. HXP-GPOVac is an egg-based, inactivated Newcastle disease virus (NDV)-vectored vaccine expressing a prefusion-stabilized SARS-CoV-2 HexaPro spike antigen. We evaluated the safety, tolerability, and immunogenicity of a single additional 10 µg dose of HXP-GPOVac administered to adults previously primed with two doses of either HXP-GPOVac or BNT162b2. Methods: Study GPO NDV-HXP-S 203 was an open-label phase II extension enrolling adults (18–75 years) who previously completed a two-dose primary series in Study 202 with either HXP-GPOVac or BNT162b2 (Pfizer–BioNTech; Comirnaty). All participants received a single additional 10 µg intramuscular dose of HXP-GPOVac ≥ 6 months after their second primary dose. Solicited local/systemic adverse events (AEs) were recorded for 7 days, unsolicited AEs through Day 28, and serious AEs (SAEs) and adverse events of special interest (AESIs) throughout follow-up. Neutralizing antibody titers (pseudovirus 50% neutralization titer, NT50) and anti-spike IgG (BAU/mL) were assessed pre-dose (Day 1) and post-vaccination through 12 months; a predefined subset underwent IFN-γ and IL-5 ELISpot. SARS-CoV-2 infection during follow-up was assessed using anti-nucleocapsid (anti-N) IgG. Symptomatic COVID-19 was identified through symptom-reported, symptom-triggered RT-PCR testing; sequencing was performed when feasible. Results: All 219 participants received HXP-GPOVac (167 primed with HXP-GPOVac and 52 with BNT162b2). Any solicited local reaction occurred in 22.2% (37/167) of HXP-GPOVac-primed and 26.9% (14/52) of BNT162b2-primed participants; any solicited systemic reaction occurred in 10.8% (18/167) and 13.5% (7/52), respectively. No vaccine-related unsolicited AEs or AESIs were reported. Three deaths occurred during the 12-month follow-up; one (a sudden cardiac death in an HXP-GPOVac-primed participant) was assessed by the safety medical team as possibly related to vaccination, and two were assessed as not related. Neutralizing antibody GMTs increased from 46.33 at baseline to 1569.04 at Day 15 in HXP-GPOVac-primed participants and from 77.25 to 841.34 in BNT162b2-primed participants; corresponding SCRs were 78.8% and 76.9%. Anti-spike IgG GMCs increased from 48.79 to 1480.14 BAU/mL and from 194.48 to 1547.88 BAU/mL, respectively. Responses declined over time but remained above baseline through 12 months. In the cellular immunity subset, post-vaccination IFN-γ responses increased, with comparatively modest IL-5 responses and no pattern suggestive of Th2 predominance. Conclusions: A single additional dose of HXP-GPOVac administered ≥6 months after primary vaccination with HXP-GPOVac or BNT162b2 was generally well tolerated and elicited robust recall humoral responses, with supportive findings of cellular immunity. Trial registration: Thai Clinical Trials Registry, TCTR20230213001.
เหตุผลที่อยู่ในฐานติดตาม
ระเบียนนี้ได้รับ Impact Signal 75/100 จากความใหม่ แหล่งเผยแพร่ ความร่วมมือ และสัญญาณในข้อมูลบรรณานุกรม คะแนนนี้ใช้จัดลำดับการติดตาม ไม่ใช่การตัดสินคุณภาพงานวิจัย
ประเด็นที่เกี่ยวข้อง: Virology and Viral Diseases · SARS-CoV-2 and COVID-19 Research · Animal Virus Infections Studies
บทบาทของนักวิจัยและสถาบันไทย
Prabda Praphasiri · Darunee Ditsungneon · Anusak Kerdsin · Sutthichai Nakphook · Jiraphut Kittiwatanachod · Kanlaya Sornwong · Suriya Naosri · Sarunpattori Khunarsa · Ponthip Wirachwong · Isariya Techatanawat · Piengthong Narakorn · Somchaiya Surichan · Chakrarat Pittayawonganon · Sopon Iamsirithaworn · Supakit Sirilak · Kriengkrai Prasert · Nakhon Phanom University · Kasetsart University · Sakon Nakhon Rajabhat University · Government of Thailand · Ministry of Public Health · Health Systems Research Institute
ข้อจำกัดของข้อมูล
หน้านี้เป็นระเบียนบรรณานุกรมและข้อมูลจากบทคัดย่อ ยังไม่ใช่บทวิเคราะห์ฉบับเต็มหรือการประเมินคุณภาพงานวิจัย ควรตรวจสอบ DOI และเอกสารต้นฉบับก่อนนำไปอ้างอิง